Vivoryon Therapeutics NV (VVY) — Cash Flow-to-Debt Ratio
Vivoryon Therapeutics NV (VVY) has a Cash Flow-to-Debt Ratio of -1.42x as of December 2025, meaning its operating cash flow of €-3.96 Million could theoretically repay -1% of its total liabilities (€2.79 Million) in one year. Check Vivoryon Therapeutics NV cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vivoryon Therapeutics NV Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Vivoryon Therapeutics NV across 15 annual periods. Also explore total assets of Vivoryon Therapeutics NV for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Vivoryon Therapeutics NV (2011–2025)
Year-by-year debt coverage analysis for Vivoryon Therapeutics NV. For market capitalisation and broader financial context, see Vivoryon Therapeutics NV (VVY) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.03x | €-8.46 Million | €2.79 Million | ▲ +46.2% |
| 2024 | -5.63x | €-19.17 Million | €3.40 Million | ▼ -18.9% |
| 2023 | -4.74x | €-21.54 Million | €4.55 Million | ▼ -5.9% |
| 2022 | -4.47x | €-21.79 Million | €4.87 Million | ▼ -216.4% |
| 2021 | -1.41x | €-11.26 Million | €7.96 Million | ▲ +64.4% |
| 2020 | -3.97x | €-14.01 Million | €3.53 Million | ▼ -9.3% |
| 2019 | -3.63x | €-11.61 Million | €3.20 Million | ▼ -46.3% |
| 2018 | -2.48x | €-6.99K | €2.82K | ▲ +62.3% |
| 2017 | -6.59x | €-12.12K | €1.84K | ▼ -197.8% |
| 2016 | -2.21x | €-13.26K | €5.99K | ▼ -4.4% |
| 2015 | -2.12x | €-12.15K | €5.73K | ▼ -10.2% |
| 2014 | -1.92x | €-10.59K | €5.51K | ▼ -138.9% |
| 2013 | -0.80x | €-8.53 Million | €10.60 Million | ▲ +69.0% |
| 2012 | -2.59x | €-12.04 Million | €4.64 Million | ▲ +24.8% |
| 2011 | -3.45x | €-14.32 Million | €4.15 Million | — |